Search

Displaying results 4301 - 4310 of 8578 in total
  1. Drug

    Patidegib

    go.drugbank.com/drugs/DB12655
    Investigational

    Patidegib has been investigated for the treatment of Conventional Chondrosarcoma.

  2. Drug

    Serlopitant

    go.drugbank.com/drugs/DB12973
    Investigational

    Serlopitant has been investigated for the treatment of Prurigo Nodularis.

  3. Drug

    PH-797804

    go.drugbank.com/drugs/DB07941
    Investigational

    PH-797804 has been investigated for the treatment of Osteoarthritis.

  4. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning

  5. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials. … Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.

  6. Drug

    Ethionamide

    go.drugbank.com/drugs/DB00609
    ApprovedInvestigationalWithdrawn

    A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)

  7. Drug

    Clofibrate

    go.drugbank.com/drugs/DB00636
    ApprovedWithdrawn

    A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

    Products: Atromid-S Cap 500mg, Atromid S Cap 500mg
  8. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    [L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. … cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors).

  9. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.

  10. Drug

    Selenomethionine

    go.drugbank.com/drugs/DB11142
    ApprovedInvestigational

    Selenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans. … *In vivo*, selenomethionine plays an essential role in acting as an antioxidant, where it depletes reactive oxygen species (ROS) and aids in the formation and recycling of glutathione, another important